The drug is a protease inhibitor, a class of drugs that work by inhibiting the enzymes the virus needs to replicate in human cells. The type of drug is used to treat other viruses, such as HIV and hepatitis C, according to CNBC, and Pfizer started clinical trials of the drug against COVID-19 in March.
Health experts told CNBC that the drug could be a game changer because it could keep people newly infected with COVID-19 out of hospitals.
Pfizer is also testing an intravenous protease inhibitor drug for patients hospitalized with COVID-19.
Read the full article here.
More articles on pharmacy:
New HHS guidelines allow nearly all healthcare providers to prescribe buprenorphine
Where are COVID-19 vaccination rates dropping the most?
US to share entire AstraZeneca COVID-19 vaccine supply with other nations
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
